Hilary M. DuBrock
Mayo Clinic
Interquartile rangeInternal medicineCardiologyRetrospective cohort studyIntensive care medicineHemodynamicsEmergency medicineLiver diseaseInterstitial lung diseasePortopulmonary hypertensionHepatopulmonary syndromeHeart failurePortal hypertensionModel for End-Stage Liver DiseaseLiver transplantationPulmonary hypertensionPulmonary arteryTransplantationIn patientVascular resistanceMedicineGastroenterology
Publications 58
#1Charles D. Burger (Mayo Clinic)H-Index: 23
#2Hilary M. DuBrock (Mayo Clinic)H-Index: 7
Last. Robert P. Frantz (Mayo Clinic)H-Index: 55
view all 6 authors...
Pulmonary hypertension is a complex condition but a relatively common manifestation of severe cardiopulmonary disease. By contrast, pulmonary arterial hypertension is uncommon and is more prevalent in young women. To better categorize patients and to guide clinical decision-making, 5 diagnostic groups and associated subgroups characterize the spectrum of disease. A multidisciplinary approach to evaluation and treatment is recommended by published guidelines and often entails referral to a design...
#1Kristin B. Highland (Cleveland Clinic)H-Index: 27
#2Rebecca CrawfordH-Index: 4
Last. Hilary M. DuBrock (Mayo Clinic)H-Index: 7
view all 0 authors...
BACKGROUND Pulmonary arterial hypertension (PAH) is characterized by progressive limitations on physical activity, right heart failure, and premature death. The World Health Organization functional classification (WHO-FC) is a clinician-rated assessment used widely to assess PAH severity and functioning, but no equivalent patient-reported version of PAH symptoms and activity limitations exists. We developed a version of the WHO-FC for self-completion by patients: the Pulmonary Hypertension Funct...
#1Catarina Aragon Pinto (Mayo Clinic)
#2Vivek N. Iyer (Mayo Clinic)H-Index: 20
Last. Alice Gallo De Moraes (Mayo Clinic)H-Index: 9
view all 9 authors...
Abstract null null Background null The lack of large hepatopulmonary syndrome cohorts undergoing liver transplantation (LT) has resulted in limited information about post-LT outcomes and expectations. null null null Methods null The long and short-term outcomes of LT in patients with hepatopulmonary syndrome (HPS) were evaluated before and after the implementation of Model for Endstage Liver Disease (MELD) score in 2002, granting exception points for patients with HPS. PubMed/Medline, Embase, We...
#1Steven D. Nathan (Inova Fairfax Hospital)H-Index: 37
#2Aaron B. Waxman (Brigham and Women's Hospital)H-Index: 46
Last. Lana Melendres-Groves (UNM: University of New Mexico)H-Index: 2
view all 15 authors...
Summary null Background null INCREASE was a randomised, placebo-controlled, phase 3 trial that evaluated inhaled treprostinil in patients with interstitial lung disease (ILD) and associated pulmonary hypertension. Treprostinil improved exercise capacity from baseline to week 16, assessed with the use of a 6-min walk test, compared with placebo. Improvements in forced vital capacity (FVC) were also reported. The aim of this post-hoc analysis was to further characterise the effects of inhaled trep...
#1Hilary M. DuBrock (Mayo Clinic)H-Index: 7
#2Charles D. Burger (Mayo Clinic)H-Index: 23
Last. Michael J. Krowka (Mayo Clinic)H-Index: 58
view all 29 authors...
BACKGROUND Right ventricular (RV) dysfunction in sepsis and septic shock has been infrequently studied and has uncertain prognostic significance. RESEARCH QUESTION Does RV function impact mortality in sepsis and septic shock? STUDY DESIGN AND METHODS We reviewed the published literature from January 1999 to April 2020 for studies evaluating adult patients with sepsis and septic shock. Study definition of RV dysfunction was used to classify patients. The primary outcome was all-cause mortality di...
#1Bradley J. Peters (Mayo Clinic)H-Index: 2
#2Alejandro A. Rabinstein (Mayo Clinic)H-Index: 85
Last. Hilary M. DuBrock (Mayo Clinic)H-Index: 7
view all 3 authors...
Myasthenia gravis and the associated pharmacologic management options could place patients at higher risk of contracting severe acute respiratory syndrome coronavirus 2 and exhibiting more severe manifestations of the novel coronavirus disease 2019 (COVID-19). Multiple agents have been studied for the management of the COVID-19, including remdesivir. To date, no published reports have evaluated the utilization of the antiviral remdesivir in patients with myasthenia gravis. We describe the first ...
#1K. del Valle (Mayo Clinic)
#2Robert P. Frantz (Mayo Clinic)H-Index: 55
Last. Hilary M. DuBrock (Mayo Clinic)H-Index: 7
view all 9 authors...
#1Hilary M. DuBrock (Mayo Clinic)H-Index: 7
#2Steven D. NathanH-Index: 37
view all 10 authors...
Pulmonary hypertension resulting from chronic lung disease such as chronic obstructive pulmonary disease and interstitial lung disease is categorized by the World Health Organization as Group 3 pulmonary hypertension. To identify the symptoms and impacts of World Health Organization Group 3 pulmonary hypertension and to capture data related to the patient experience of this disease, qualitative research interviews were undertaken with 3 clinical experts and 14 individuals with pulmonary hyperten...
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.